Clinical Trials Logo

Filter by:
  • Completed  
  • « Prev · Page [6]
NCT ID: NCT00312208 Completed - Breast Cancer Clinical Trials

Docetaxel in Breast Cancer

Start date: November 2001
Phase: Phase 3
Study type: Interventional

Primary objective : - To compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by docetaxel in operable adjuvant breast cancer HER2neu negative patients with positive axillary lymph nodes. Secondary objectives : - To compare toxicity and quality of life between the 2 above-mentioned arms. - To evaluate pathologic and molecular markers for predicting efficacy.

NCT ID: NCT00141193 Completed - Colorectal Adenoma Clinical Trials

Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)

PRESAP
Start date: February 2001
Phase: Phase 3
Study type: Interventional

This study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial to compare the efficacy and safety of celecoxib 400mg QD versus placebo in reducing the occurrence of new colorectal adenomas post-polypectomy at Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.

NCT ID: NCT00097786 Completed - Clinical trials for Diabetes Mellitus, Type 2

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

Navigator
Start date: January 2002
Phase: Phase 3
Study type: Interventional

This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking.

NCT ID: NCT00088530 Completed - Clinical trials for Lymphoma, Non-Hodgkin

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Start date: July 2004
Phase: Phase 3
Study type: Interventional

BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore).

NCT ID: NCT00077792 Completed - Clinical trials for Myocardial Infarction

Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)

Start date: October 2002
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after randomization in patients with acute ST-segment elevation myocardial infarction who are eligible to receive fibrinolytic therapy

NCT ID: NCT00070720 Completed - Pregnancy Clinical Trials

Improving Perinatal Care in Latin America

Start date: September 2003
Phase: Phase 4
Study type: Interventional

Many obstetrical interventions used in Latin America, as in other parts of the world, have been shown to be ineffective or harmful, while effective interventions remain underutilized. This study will develop and evaluate an intervention intended to implement two evidence-based practices among birth attendants in Latin America, the selective use of episiotomies and active management of the third stage of labor.

NCT ID: NCT00021255 Completed - Breast Neoplasms Clinical Trials

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Start date: April 2001
Phase: Phase 3
Study type: Interventional

Primary objective: - Compare disease-free survival in women with HER2-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin. Secondary objective: - Compare overall survival of patients treated with these regimens. - Compare the toxic effects (including cardiac) of these regimens in these patients. - Compare quality of life of patients treated with these regimens. - Compare pathologic and molecular markers for predicting efficacy of these regimens in these patients. - For substudy: Compare peripheral levels of shed HER2-neu extracellular domain with fluorescence in situ hybridization in predicting outcome in patients treated with these regimens.